Paradox Immunotherapeutics Incorporated

3 records totalling $287,119.00 CAD, from official Government of Canada open data.

Embed this chart

<iframe src="https://ottawaspends.ca/en/embed/fy/recipient/paradox-immunotherapeutics-incorporated" width="100%" height="360" style="border:0" title="OttawaSpends.ca chart" loading="lazy"></iframe>

By department

National Research Council Canada

$287,119

3 records

Records

Paradox Immunotherapeutics Incorporated $183,595.00

National Research Council Canada | Conseil national de recherches Canada

Industrial Research Assistance Program – Contributions to Firms

FY 2022-2023

Canada

Identification, characterization, and screening of monoclonal antibodies for the treatment of ? and ?-light chain amyloidosis and drug discovery for ALECT2 amyloidosis. Potential candidates will be sc...

Paradox Immunotherapeutics Incorporated $73,524.00

National Research Council Canada | Conseil national de recherches Canada

Industrial Research Assistance Program – Contributions to Firms

FY 2024-2025

Canada

As part of Multinational Corporate Collaboration Program, the project “PACAAL” will focus on using established mouse models to evaluate 4 top candidate antibodies co-developed by Paradox and Eli Lilly...

Paradox Immunotherapeutics Incorporated $30,000.00

National Research Council Canada | Conseil national de recherches Canada

Industrial Research Assistance Program – Youth Employment Program

FY 2022-2023

Canada

AL amyloidosis is a life-threatening disease caused by the misfolding of free immunoglobulin light chains (LC) which deposit as light chain amyloid (AL) in the heart, kidney, and nervous system, causi...